Literature DB >> 12569067

A unique phenotype of 5-HT2C, agonist-induced GTPgamma35S binding, transferable to 5-HT2A and 5-HT2B, upon swapping intracellular regions.

Glen L Alberts1, Christopher L Chio, Wha Bin Im, Jerry L Slightom.   

Abstract

1 The human 5-HT(2C) receptor, when expressed heterologously in various mammalian cell lines (HEK293, SH-EP and NIH-3T3) at various receptor densities (6 to 45 pmol mg(-1) protein), mediates robust agonist-induced GTPgamma(35)S binding from coupling to G(i) subtypes of G proteins, in addition to G(q/11). Such a phenotype, however, was not seen with the human 5-HT(2A) and 5-HT(2B) receptors, indicating their common pathway with 5-HT(2C) limited to G(q/11), not including G(i). 2 Because intracellular regions are largely responsible for signalling pathways, we prepared the chimeras of the 5-HT(2A) and 5-HT(2B) receptors where the second and third intracellular loops, and the C-terminal region were replaced with the 5-HT(2C) counterparts. 3 The chimeras showed robust agonist-induced GTPgamma(35)S binding. Relative intrinsic efficacies of agonists from the GTPgamma(35)S binding were nearly identical to the reported values for their parent receptors as measured with Ca(2+) or [(3)H]-inositol phosphate accumulation. Also the chimeras displayed the same ligand-binding properties as the parent receptors. 4 We conclude that the phenotype of agonist-induced GTPgamma(35)S binding is unique to 5-HT(2C) among the 5-HT(2) receptor family, and is transferable to 5-HT(2A) and 5-HT(2B), upon swapping intracellular sequences, without altering their receptor pharmacology.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12569067      PMCID: PMC1573684          DOI: 10.1038/sj.bjp.0705058

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  26 in total

1.  Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs.

Authors:  E Sanders-Bush; M Breeding
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension.

Authors:  R M Horton; H D Hunt; S N Ho; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

3.  Serotonin receptors in the human brain--IV. Autoradiographic mapping of serotonin-2 receptors.

Authors:  A Pazos; A Probst; J M Palacios
Journal:  Neuroscience       Date:  1987-04       Impact factor: 3.590

Review 4.  5-Hydroxytryptamine receptor subtypes: molecular and functional diversity.

Authors:  F Saudou; R Hen
Journal:  Adv Pharmacol       Date:  1994

5.  RNA editing of the human serotonin 5-HT2C receptor alters receptor-mediated activation of G13 protein.

Authors:  R D Price; D M Weiner; M S Chang; E Sanders-Bush
Journal:  J Biol Chem       Date:  2001-09-25       Impact factor: 5.157

6.  Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors.

Authors:  L H Tecott; L M Sun; S F Akana; A M Strack; D H Lowenstein; M F Dallman; D Julius
Journal:  Nature       Date:  1995-04-06       Impact factor: 49.962

7.  Regulation of polyphosphoinositide-specific phospholipase C activity by purified Gq.

Authors:  A V Smrcka; J R Hepler; K O Brown; P C Sternweis
Journal:  Science       Date:  1991-02-15       Impact factor: 47.728

8.  High affinity agonist binding to cloned 5-hydroxytryptamine2 receptors is not sensitive to GTP analogs.

Authors:  F G Szele; D B Pritchett
Journal:  Mol Pharmacol       Date:  1993-06       Impact factor: 4.436

9.  Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking.

Authors:  Didier Cussac; Adrian Newman-Tancredi; Delphine Duqueyroix; Valérie Pasteau; Mark J Millan
Journal:  Mol Pharmacol       Date:  2002-09       Impact factor: 4.436

Review 10.  Phosphoinositide system-linked serotonin receptor subtypes and their pharmacological properties and clinical correlates.

Authors:  S C Pandey; J M Davis; G N Pandey
Journal:  J Psychiatry Neurosci       Date:  1995-05       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.